Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1314 injection in active moderate-to-severe Graves ophthalmopathy
CTR20221282Phase 2Terminated
- Sponsor
- Suzhou Sundia Biotech Co., Ltd.
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vunakizumab in Graves Orbitopathy (GO), sponsored by Suzhou Sundia Biotech Co., Ltd. Primary endpoint: Proptosis responder rate at Week 16 (study eye). Started May 2022; status: terminated.
02
Drugs
vunakizumab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20221282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221282.